Download PDF
Dtsch Med Wochenschr 2004; 129(9): 439-442
DOI: 10.1055/s-2004-820065
Der Arzneistoff
Pharmakologie / Prävention
© Georg Thieme Verlag Stuttgart · New York

Acetylsalicylsäure - ein geeignetes Mittel zur Krebsprävention?

Aspirin use for cancer prevention?D. Taubert1 , R. Berkels1 , E. Schömig1
  • 1Institut für Pharmakologie, Klinikum der Universität zu Köln
Further Information

Publication History

eingereicht: 18.11.2003

akzeptiert: 15.1.2004

Publication Date:
17 February 2004 (online)

Also available at
    Permissions and Reprints

Acetylsalicylsäure (ASS, Aspirin® u. a.) ist ein Vertreter der NSAID („nonsteroidal antiinflammatory drugs“). (Die gelegentlich anzutreffende Unterscheidung zwischen ASS und NSAID ist irreführend. Der Begriff NSAID bezeichnet in Abgrenzung zu Opioid-Analgetika und Glucocorticoid-Antiphlogistika eine Gruppe von nichtsteroidalen Substanzen mit zumeist sauren Eigenschaften, die durch einen gemeinsamen Wirkmechanismus (Hemmung der Prostaglandinsynthese) und klinisch durch analgetische, antipyretische und antiphlogistische Wirkungen charakterisiert sind. Somit ist ASS ein prototypisches NSAID.)

Neben den bekannten antiinflammatorischen, analgetischen und antipyretischen Effekten besitzt ASS eine ebenfalls gut untersuchte thrombozytenaggregationshemmende Wirkung, die klinisch zur Prävention thrombotischer vaskulärer Ereignisse, insbesondere des Myokardinfarktes, genutzt wird [1] [2]. Seit den 1980er Jahren gibt es zunehmend Hinweise auf eine protektive Wirkung von ASS in der Prävention maligner Tumorerkrankungen. Die Ergebnisse jüngster epidemiologischer [3] [4] und klinischer Studien [5] [6] haben eine intensive Diskussion zum Nutzen von ASS in der Krebsprävention angestoßen.

Literatur

  • 1 Anonymous . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
    Google Scholar
  • 2 Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force.  Ann Intern Med. 2002;  136 161-172
    Google Scholar
  • 3 Garcia-Rodriguez L A, Huerta-Alvarez C. Reduced risk of colorectal cancer amonglong-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.  Epidemiology. 2001;  12 88-93
    Google Scholar
  • 4 Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, La Vecchia C. Aspirin use and cancers of the upper aerodigestive tract.  Br J Cancer. 2003;  88 672-674
    Google Scholar
  • 5 Baron J A, Cole B F, Sandler R S, Haile R W, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers R W, Rothstein R, Burke C A, Snover D C, Church T R, Allen J I, Beach M, Beck G J, Bond J H, Byers T, Greenberg E R, Mandel J S, Marcon N, Mott L A, Pearson L, Saibil F, van Stolk R U. A randomized trial of aspirin to prevent colorectal adenomas.  N Engl J Med. 2003;  348 891-899
    Google Scholar
  • 6 Sandler R S, Halabi S, Baron J A, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas J M, Karp D D, Loprinzi C L, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.  N Engl J Med. 2003;  348 883-890
    Google Scholar
  • 7 Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirinlike drugs.  Nat New Bio. 1971;  231 232-235
    Google Scholar
  • 8 Thun M J, Henley S J, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.  J Natl Cancer Inst. 2002;  94 252-266
    Google Scholar
  • 9 Chan T A. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention.  Lancet Oncol. 2002;  3 166-174
    Google Scholar
  • 10 Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.  Gastroenterology. 1994;  107 1183-1188
    Google Scholar
  • 11 Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.  Clin Cancer Res. 2003;  9 1604-1610
    Google Scholar
  • 12 Anderson W F, Umar A, Viner J L, Hawk E T. The role of cyclooxygenase inhibitors in cancer prevention.  Curr Pharm Des. 2002;  8 1035-1062
    Google Scholar
  • 13 Sheehan K M, Sheahan K, O’Donoghue D P, MacSweeney F, Conroy R M, Fitzgerald D J, Murray F E. The relationship between cyclooxygenase-2 expression and colorectal cancer.  Jama. 1999;  282 1254-1257
    Google Scholar
  • 14 Steinbach G, Lynch P M, Phillips R K, Wallace M H, Hawk E, Gordon G B, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su L K, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.  N Engl J Med. 2000;  342 1946-1952
    Google Scholar
  • 15 Sheng H, Shao J, Washington M K, DuBois R N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.  J Biol Chem. 2001;  276 18075-18081
    Google Scholar
  • 16 Gupta R A, Tan J, Krause W F, Geraci M W, Willson T M, Dey S K, DuBois R N. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.  Proc Natl Acad Sci USA. 2000;  97 13275-13280
    Google Scholar
  • 17 Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells.  Cell. 1998;  93 705-716
    Google Scholar
  • 18 Chan T A, Morin P J, Vogelstein B, Kinzler K W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis.  Proc Natl Acad Sci USA. 1998;  95 681-686
    Google Scholar
  • 19 Hannun Y A. Functions of ceramide in coordinating cellular responses to stress.  Science. 1996;  274 1855-1859
    Google Scholar
  • 20 Scorrano L, Penzo D, Petronilli V, Pagano F, Bernardi P. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha aopototic signaling.  J Biol Chem. 2001;  276 12 035-12 040
    Google Scholar
  • 21 Thun M J, Namboodiri M M, Heath C W. Aspirin use and reduced risk of fatal colon cancer.  N Engl J Med. 1991;  325 1593-1596
    Google Scholar
  • 22 Giovannucci E, Egan K M, Hunter D J, Stampfer M J, Colditz G A, Willett W C, Speizer F E. Aspirin and the risk of colorectal cancer in women.  N Engl J Med. 1995;  333 609-614
    Google Scholar
  • 23 Meade E A, Smith W L, DeWitt D L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.  J Biol Chem. 1993;  268 6610-6614
    Google Scholar
  • 24 Patrono C, Patrignani P, Garcia Rodriguez L A. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.  J Clin Invest. 2001;  108 7-13
    Google Scholar
  • 25 Xu X M, Sansores-Garcia L, Chen X M, Matijevic-Aleksic N, Du M, Wu K K. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate.  Proc Natl Acad Sci USA. 1999;  96 5292-5297
    Google Scholar
  • 26 Wu J, Xia H H, Tu S P, Fan D M, Lin M C, Kung H F, Lam S K, Wong B C. 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer.  Carcinogenesis. 2003;  24 243-247
    Google Scholar
  • 27 Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation.  Science. 1996;  274 1383-1385
    Google Scholar
  • 28 He T C, Chan T A, Vogelstein B, Kinzler K W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.  Cell. 1999;  99 335-345
    Google Scholar
  • 29 Huls G, Koornstra J J, Kleibeuker J H. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.  Lancet. 2003;  362 230-232
    Google Scholar
  • 30 Dihlmann S, Klein S, Doeberitz M K. Reduction of beta-Catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin Is Caused by an Increased Stabilization of Phosphorylated beta-Catenin.  Mol Cancer Ther. 2003;  2 509-516
    Google Scholar
  • 31 Awtry E H, Loscalzo J. Aspirin.  Circulation. 2000;  101 1206-1218
    Google Scholar
  • 32 Amann R, Peskar B A. Anti-inflammatory effects of aspirin and sodium salicylate.  Eur J Pharmacol. 2002;  447 1-9
    Google Scholar
  • 33 Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.  Gastroenterology. 1994;  107 117-120
    Google Scholar
  • 34 Moody G A, Jayanthi V, Probert C S, MacKay H, Mayberry J F. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.  Eur J Gastroenterol Hepatol. 1996;  8 1179-1183
    Google Scholar
  • 35 Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells.  Carcinogenesis. 2003;  24 443-451
    Google Scholar
  • 36 Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.  Aliment Pharmacol Ther. 2003;  18 10-14 (Suppl 2)
    Google Scholar
  • 37 Bus P J, Nagtegaal I D, Verspaget H W, Lamers C B, Geldof H, Van Krieken J H, Griffioen G. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?.  Aliment Pharmacol Ther. 1999;  13 1397-1402
    Google Scholar
  • 38 Levin B. Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention.  J Natl Cancer Inst. 2003;  95 697-699
    Google Scholar
  • 39 Levi F, Lucchini F, Negri E, La Vecchia C. Worldwide patterns of cancer mortality 1990 - 94.  Eur J Cancer Prev. 1999;  8 381-400
    Google Scholar
  • 40 Steering Committee of the Physicians’ Health Study Research Group . Final report on the aspirin component of the ongoing Physicians’ Health Study.  N Engl J Med. 1989;  321 129-135
    Google Scholar
  • 41 Imperiale T F. Aspirin and the prevention of colorectal cancer.  N Engl J Med. 2003;  348 879-880
    Google Scholar
  • 42 Suleiman S, Rex D K, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis.  Gastroenterology. 2002;  122 78-84
    Google Scholar
  • 43 Subbaramaiah K, Hart J C, Norton L, Dannenberg A J. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways.  J Biol Chem. 2000;  275 14 838-14 845
    Google Scholar
  • 44 Kune G A, Kune S, Watson L F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.  Cancer Res. 1988;  48 4399-4404
    Google Scholar
  • 45 Rosenberg L, Palmer J R, Zauber A G, Warshauer M E, Stolley P D, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of largebowel cancer.  J Natl Cancer Inst. 1991;  83 355-358
    Google Scholar
  • 46 Suh O, Mettlin C, Petrelli N J. Aspirin use, cancer, and polyps of the large bowel.  Cancer. 1993;  72 1171-1177
    Google Scholar
  • 47 Muscat J E, Stellman S D, Wynder E L. Nonsteroidal antiinflammatory drugs and colorectal cancer.  Cancer. 1994;  74 1847-1854
    Google Scholar
  • 48 Peleg I I, Maibach H T, Brown S H, Wilcox C M. Aspirin and nonsteroidal antiinflammatory drug use and the risk of subsequent colorectal cancer.  Arch Intern Med. 1994;  154 394-399
    Google Scholar
  • 49 Reeves M J, Newcomb P A, Trentham-Dietz A, Storer B E, Remington P L. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women.  Cancer Epidemiol Biomarkers Prev. 1996;  5 955-960
    Google Scholar
  • 50 La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, Falcini A, Decarli A. Aspirin and colorectal cancer.  Br J Cancer. 1997;  76 675-677
    Google Scholar
  • 51 Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma.  Cancer. 1998;  82 2326-2333
    Google Scholar
  • 52 Friedman G D, Coates A O, Potter J D, Slattery M L. Drugs and colon cancer.  Pharmacoepidemiol Drug Safety. 1998;  7 99-106
    Google Scholar
  • 53 Neugut A I, Rosenberg D J, Ahsan H, Jacobson J S, Wahid N, Hagan M, Rahman M I, Khan Z R, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon.  Cancer Epidemiol Biomarkers Prev. 1998;  7 869-873
    Google Scholar
  • 54 Paganini-Hill A, Chao A, Ross R K, Henderson B E. Aspirin use and chronic diseases: a cohort study of the elderly.  Bmj. 1989;  299 1247-1250
    Google Scholar
  • 55 Thun M J, Namboodiri M M, Calle E E, Flanders W D, Heath C W. Aspirin use and risk of fatal cancer.  Cancer Res. 1993;  53 1322-1327
    Google Scholar
  • 56 Schreinemachers D M, Everson R B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study.  Epidemiology. 1994;  5 138-146
    Google Scholar
  • 57 Giovannucci E, Rimm E B, Stampfer M J, Colditz G A, Ascherio A, Willett W C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.  Ann Intern Med. 1994;  121 241-246
    Google Scholar
  • 58 Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001.  Eur J Cancer Prev. 2002;  11 535-542
    Google Scholar
  • 59 Harris R E, Namboodiri K K, Farrar W B. Nonsteroidal antiinflammatory drugs and breast cancer.  Epidemiology. 1996;  7 203-205
    Google Scholar
  • 60 Coogan P F, Rao S R, Rosenberg L, Palmer J R, Strom B L, Zauber A G, Stolley P D, Shapiro S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer.  Prev Med. 1999;  29 72-76
    Google Scholar
  • 61 Friedman G D, Ury H K. Initial screening for carcinogenicity of commonly used drugs.  J Natl Cancer Inst. 1980;  65 723-733
    Google Scholar
  • 62 Egan K M, Stampfer M J, Giovannucci E, Rosner B A, Colditz G A. Prospective study of regular aspirin use and the risk of breast cancer.  J Natl Cancer Inst. 1996;  88 988-993
    Google Scholar
  • 63 Harris R E, Kasbari S, Farrar W B. Prospective study of nonsteoridal antiinflammatory drugs and breast cancer.  Oncol Rep. 1999;  6 71-73
    Google Scholar
  • 64 Tzonou A, Polychronopoulou A, Hsieh C C, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer.  Int J Cancer. 1993;  55 408-410
    Google Scholar
  • 65 Cramer D W, Harlow B L, Titus-Ernstoff L, Bohlke K, Welch W R, Greenberg E R. Over-the-counter analgesics and risk of ovarian cancer.  Lancet. 1998;  351 104-107
    Google Scholar
  • 66 Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study.  Ann Oncol. 2000;  11 1171-1173
    Google Scholar
  • 67 Rosenberg L, Palmer J R, Rao R S, Coogan P F, Strom B L, Zauber A G, Stolley P D, Shapiro S. A case-control study of analgesic use and ovarian cancer.  Cancer Epidemiol Biomarkers Prev. 2000;  9 933-937
    Google Scholar
  • 68 Moysich K B, Mettlin C, Piver M S, Natarajan N, Menezes R J, Swede H. Regular use of analgesic drugs and ovarian cancer risk.  Cancer Epidemiol Biomarkers Prev. 2001;  10 903-906
    Google Scholar
  • 69 Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig K L, Shore R E. Aspirin and epithelial ovarian cancer.  Prev Med. 2001;  33 682-687
    Google Scholar
  • 70 Leitzmann M F, Stampfer M J, Ma J, Chan J M, Colditz G A, Willett W C, Giovannucci E. Aspirin use in relation to risk of prostate cancer.  Cancer Epidemiol Biomarkers Prev. 2002;  11 1108-1111
    Google Scholar
  • 71 Farrow D C, Vaughan T L, Hansten P D, Stanford J L, Risch H A, Gammon M D, Chow W H, Dubrow R, Ahsan H, Mayne S T, Schoenberg J B, West A B, Rotterdam H, Fraumeni J F, Blot W J. Use of aspirin and other 10 nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.  Cancer Epidemiol Biomarkers Prev. 1998;  7 97-102
    Google Scholar
  • 72 Sharp L, Chilvers C E, Cheng K K, McKinney P A, Logan R F, Cook-Mozaffari P, Ahmed A, Day N E. Risk factors for squamous cell carcinoma of the oesophagus in women: a case-control study.  Br J Cancer. 2001;  85 1667-1670
    Google Scholar
  • 73 Funkhouser E M, Sharp G B. Aspirin and reduced risk of esophageal carcinoma.  Cancer. 1995;  76 1116-1119
    Google Scholar
  • 74 Akre K, Ekstrom A M, Signorello L B, Hansson L E, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden.  Br J Cancer. 2001;  84 965-968
    Google Scholar
  • 75 Anderson K E, Johnson T W, Lazovich D, Folsom A R. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer.  J Natl Cancer Inst. 2002;  94 1168-1171
    Google Scholar

Dr. Dirk Taubert

Gleueler Str. 24

50931 Köln

Phone: 0221-4784196

Fax: 0221-4785022

Email: dirk.taubert@medizin.uni-koeln.de